Cirrhosis Pipeline Summary

DelveInsight�s, �Cirrhosis - Pipeline Insight, 2026� report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

� Global coverage

Cirrhosis: Understanding

Cirrhosis: Overview

Cirrhosis is a chronic, progressive liver disease characterized by extensive scarring (fibrosis) and the replacement of healthy liver tissue with scar tissue, which gradually impairs the liver's ability to function properly. The liver performs essential functions such as filtering toxins, producing proteins involved in blood clotting, storing nutrients, and supporting digestion. As cirrhosis progresses, increasing amounts of scar tissue disrupt the normal structure and blood flow within the liver, leading to reduced liver function and the development of serious complications. Although early-stage cirrhosis may not cause noticeable symptoms, advanced disease can result in liver failure and significantly impact overall health.

Cirrhosis develops as the result of long-term liver injury from a variety of underlying conditions. The most common causes include chronic viral hepatitis B and hepatitis C infections, long-term excessive alcohol consumption, and nonalcoholic fatty liver disease (NAFLD), particularly its progressive form known as nonalcoholic steatohepatitis (NASH). Other causes include autoimmune hepatitis, inherited metabolic disorders such as hemochromatosis and Wilson disease, diseases affecting the bile ducts including primary biliary cholangitis and primary sclerosing cholangitis, as well as prolonged exposure to certain medications, toxins, or chronic liver infections. Regardless of the underlying cause, persistent liver injury triggers inflammation and progressive scarring that eventually culminates in cirrhosis.

Cirrhosis develops when chronic liver injury causes persistent inflammation and activation of hepatic stellate cells, resulting in excessive collagen deposition and fibrosis. Progressive scar tissue and regenerative nodules disrupt the normal liver structure and blood flow, leading to portal hypertension and impaired liver function. Over time, these changes reduce the liver's ability to perform essential metabolic, synthetic, and detoxification functions, ultimately leading to liver failure if left untreated.

Cirrhosis is diagnosed using a combination of medical history, physical examination, blood tests, and imaging studies. Liver function tests help assess liver damage, while ultrasound, transient elastography (FibroScan), CT, or MRI evaluate liver structure and the extent of fibrosis. In some cases, a liver biopsy may be performed to confirm the diagnosis and determine disease severity.

Treatment of cirrhosis focuses on managing the underlying cause, slowing disease progression, and preventing complications. Depending on the cause, management may include antiviral therapy, alcohol cessation, weight reduction, or immunosuppressive treatment. Patients are also treated for complications such as portal hypertension, ascites, and hepatic encephalopathy, while liver transplantation remains the definitive treatment for advanced or decompensated cirrhosis.

"Cirrhosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cirrhosis pipeline landscape is provided which includes the disease overview and Cirrhosis treatment guidelines. The assessment part of the report embraces, in depth Cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

� The companies and academics are working to assess challenges and seek opportunities that could influence Cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve Cirrhosis.

Cirrhosis Emerging Drugs Chapters

This segment of the Cirrhosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cirrhosis Emerging Drugs

� Efimosfermin Alfa: GSK

Efimosfermin Alfa (GSK6519754) is an investigational, once-monthly subcutaneous injection of a long-acting variant of fibroblast growth factor 21 (FGF21) being developed by GSK for metabolic dysfunction-associated steatohepatitis (MASH), including MASH with cirrhosis. The therapy is designed to regulate key metabolic pathways, thereby decreasing liver fat, ameliorating liver inflammation, and reversing liver fibrosis. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Liver Cirrhosis.

� AZD2389: AstraZeneca

AZD2389 is an investigational, first-in-class, orally administered small-molecule fibroblast activation protein (FAP) inhibitor which selectively inhibits the enzymatic activity of FAP, a serine protease that is highly expressed in activated hepatic fibroblasts and is associated with liver fibrogenesis. AZD2389 is designed to inhibit FAP-mediated cleavage of substrates such as fibroblast growth factor 21 (FGF21) and ?2-antiplasmin (?2-AP), thereby preserving their activity and modulating pathways involved in liver fibrosis. Through inhibition of FAP, AZD2389 is intended to target the underlying fibrotic process and has the potential to slow fibrosis progression in patients with cirrhosis. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Liver Cirrhosis.

� BI 3802876: Boehringer Ingelheim

BI 3802876 is an investigational therapeutic candidate being developed for the treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The drug is administered as an intravenous infusion and is currently being evaluated in a Phase IIa clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with compensated cirrhosis. BI 3802876 is being developed with the aim of improving liver health in patients with this condition. However, the company has not publicly disclosed the drug's molecular target, mechanism of action, or the biological pathways through which it exerts its therapeutic effects. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Cirrhosis.

� RTX001: Resolution Therapeutics

RTX001 is an engineered autologous Regenerative Macrophage Therapy (RMT) being developed by Resolution Therapeutics for the treatment of end-stage liver disease associated with decompensated liver cirrhosis. The therapy uses patient-derived macrophages engineered with IL-10 and MMP-9 mRNA to enhance their natural regenerative properties and increase their anti-inflammatory and anti-fibrotic activity, with the aim of promoting liver repair and improving the durability of therapeutic effects. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Cirrhosis.

Further product details are provided in the report��..

Cirrhosis: Therapeutic Assessment

This segment of the report provides insights about the different Cirrhosis drugs segregated based on following parameters that define the scope of the report, such as:

� Major Players in Cirrhosis

There are approx. 40+ key companies which are developing the therapies Cirrhosis. The companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. Phase III include, GSK, and others.

� Phases

DelveInsight�s report covers around 50+ products under different phases of clinical development like

� Late stage products (Phase III)

� Mid-stage products (Phase II)

� Early-stage product (Phase I) along with the details of

� Pre-clinical and Discovery stage candidates

� Discontinued & Inactive candidates

� Route of Administration

Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

� Intra-articular

� Intraocular

� Intrathecal

� Intravenous

� Ophthalmic

� Oral

� Parenteral

� Subcutaneous

� Topical

� Transdermal

� Molecule Type

Products have been categorized under various Molecule types such as

� Oligonucleotide

� Peptide

� Small molecule

� Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cirrhosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cirrhosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cirrhosis drugs.

Cirrhosis Report Insights

� Cirrhosis Pipeline Analysis

� Therapeutic Assessment

� Unmet Needs

� Impact of Drugs

Cirrhosis Report Assessment

� Pipeline Product Profiles

� Therapeutic Assessment

� Pipeline Assessment

� Inactive drugs assessment

� Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

� How many companies are developing Cirrhosis drugs?

� How many Cirrhosis drugs are developed by each company?

� How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cirrhosis?

� What are the key collaborations (Industry�Industry, Industry�Academia), Mergers and acquisitions, licensing activities related to the Cirrhosis therapeutics?

� What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

� What are the clinical studies going on for Cirrhosis and their status?

� What are the key designations that have been granted to the emerging drugs?

Key Players

� Galectin Therapeutics

� AstraZeneca

� Boehringer Ingelheim

� Merck Sharp & Dohme

� Hanmi Pharmaceuticals

� Can-fite Biopharma

� Lipocine Inc.

� OHARA Pharmaceutical Co.,Ltd.

� PharmaIN

� Resolution Therapeutics Limited

� GSK

Key Products

� Belapectin

� AZD2389

� BI 3802876

� Efinopegdutide

� Namodenoson

� LPCN 1148

� Foscenvivint(OP-724)

� PHIN-214

� RTX001

� Efimosfermin Alfa

� AZD3974